FBIO
- Fortress Biotech, Inc.
()
Overview
Company Summary
Fortress Biotech, Inc., or FBIO, is a biopharmaceutical company that focuses on developing and commercializing innovative pharmaceutical and biotechnology products. The company operates through its various subsidiary companies, each specializing in specific therapeutic areas.
FBIO's approach is to acquire or establish subsidiary companies to pursue the development of drugs and therapies that have the potential to address unmet medical needs. They leverage the expertise of these subsidiary companies, which act as standalone entities with their own management teams, to develop a diverse pipeline of products.
Some of the subsidiary companies under FBIO include Cyprium Therapeutics, which focuses on developing treatments for rare genetic diseases, Aevitas Therapeutics, which develops gene therapies for life-threatening diseases, Mustang Bio, which concentrates on novel cell and gene therapies for hematologic cancers, and Checkpoint Therapeutics, which develops targeted small molecules and antibody-drug conjugates for oncology.
The company also has subsidiaries like Tamid Bio, Journey Medical, and Avenue Therapeutics, focusing on various therapeutic areas such as dermatology, addiction medicine, and pain management.
By utilizing the strengths and resources of these subsidiary companies, Fortress Biotech aims to efficiently bring innovative drugs and therapies to market. They employ a collaboration-based model, partnering with academic institutions, research centers, and other biopharmaceutical companies to share expertise and foster innovation.
FBIO's ultimate goal is to improve patient outcomes by developing breakthrough treatments for a wide range of diseases and medical conditions. Through its subsidiary companies, Fortress Biotech strives to make a meaningful impact in the field of biopharmaceuticals and contribute to the advancement of healthcare worldwide.